Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer

Maitland, Michael L.; Wilcox, Rebecca; Hogarth, D. Kyle; Desai, Apurva A.; Caligiuri, Phil; Abrahams, Cyril; Salgia, Ravi

doi:10.1016/j.lungcan.2006.07.017

Cited by 13 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suzuki et al [18] have proposed topotecan for salvage chemotherapy in case of pre-existing ILD because of the low incidence of exacerbation with that drug. Nevertheless, a case of diffuse alveolar damage has been published in that situation [19]. Amrubicine, a new anthracyclin, used in the management of SCLC in East Asia, has been shown to be associated with a very significant increased risk of severe ILD in case of pre-existing fibrosis and is thus considered as contra-indicated in such a condition.…”

Section: Pulmonary Diseasesmentioning

confidence: 99%

“…In a series of 4447 elderly Medicare beneficiaries with lung cancer [3], 39% had COPD and 13% had congestive heart failure (CHF). In a series of 484 cases of small cell lung cancer (SCLC) diagnosed at the Innsbruck University Hospital and associated institutions between 1991 and 2011 [4], cardiovascular disease was present in 56.9%, COPD in 51.9%, other malignancies in 19.7%, diabetes in 19.7%, neurologic disease including stroke in 11.9% and renal failure in 7.4%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Sculier¹,

Botta²,

Bucalau³

et al. 2015

Lung Cancer

View full text Add to dashboard Cite

Section: Pulmonary Diseasesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Sculier¹,

Botta²,

Bucalau³

et al. 2015

Lung Cancer

View full text Add to dashboard Cite

“…This agent is rarely associated with pulmonary toxicity. In few case reports, some of the pulmonary-related complications of topotecan include diffuse alveolar damage, nonspecific interstitial pneumonia (NSIP), and obliterative bronchiolitis [84] .…”

Section: Topoisomerase Inhibitorsmentioning

confidence: 99%

Anticancer therapy and lung injury: molecular mechanisms

Mok

Jhaveri

et al. 2018

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Chemotherapy and radiation therapy are two mainstream strategies applied in the treatment of cancer that is not operable. Patients with hematological or solid tumor malignancies substantially benefit from chemotherapeutic drugs and/or ionizing radiation delivered to the site of malignancy. However, considerable adverse effects, including lung inflammation and fibrosis, are associated with the use of these treatment modalities. Areas covered: As we move toward the era of precision health, we are compelled to understand the molecular basis of chemoradiation-induced pathological lung remodeling and to develop effective treatment strategies that mitigate the development of chronic lung disease (i.e. fibrosis) in cancer patients. The review discusses chemotherapeutic agents that are reported to induce or associate with acute and/or chronic lung injury. Expert commentary: There is a need to molecularly understand how chemotherapeutic drugs induce or associate with respiratory toxicities and whether such characteristics are inherently related to their antitumor effect or are collateral. Once such mechanisms have been identified and/or fully characterized, they may be able to guide disease-management decisions including effective intervention strategies for the adverse effects. In the meantime, radiation oncologists should be judicious on the dose of radiation delivered to the lungs, the volume of lung irradiated, and concurrent use of chemotherapeutic drugs.

show abstract

“…Interferons + + [113] Irinotecan + [114] Methotrexate + + + [33,34] Mitomycin C + + [88,115] Nitrosourea + + + [116,117] Oxaliplatin + + [118,119] Paclitaxel + + [120,121] Topotecan + + [122,123] Transtuzumab + [124] Vinblastine + [125] Expert Rev. Anticancer Ther.…”

Section: Medical Historymentioning

confidence: 99%

Antineoplastic therapy-induced pulmonary toxicity

Sadowska¹,

Specenier²,

Germonpré

et al. 2013

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is complex and should be based on the medical history, clinical, radiological and pathological findings. None of them are specific but they can guide the diagnostic process. The treatment of pulmonary abnormalities caused by chemotherapy is mostly supportive and based on cessation of the causative agent. However, the therapeutic options in oncology setting are usually limited thus the decision about changing the treatment should be taken with caution.

show abstract

Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer

Cited by 13 publications

References 5 publications

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Medical anticancer treatment of lung cancer associated with comorbidities: A review

Anticancer therapy and lung injury: molecular mechanisms

Antineoplastic therapy-induced pulmonary toxicity

Contact Info

Product

Resources

About